Update on efficacy of the approved remdesivir regimen for treatment of COVID-19: a systematic review with meta-analysis and trial sequential analysis of randomized controlled trials

References

• World Health Organization. R&D Blueprint and COVID-19. The World Health Organization; 2021. https://bit.ly/3rmQRCw. Accessed January 12.
   Google Scholar
• United States Food and Drug Administration. NDA 214787: cross Discipline Team Leader, Division Director and ODE Director Summary Review. United States Food and Drug Administration; 2020. https://bit.ly/2TiAYOz. Accessed October 23.
   Google Scholar
• Malin JJ, Suárez I, Priesner V, et al. Remdesivir against COVID-19 and other viral diseases. Clin Microbiol Rev. 2020;34(1):e00162–00120. doi: 10.1128/CMR.00162-20.
   PubMed Web of Science ®Google Scholar
• Saha A, Sharma AR, Bhattacharya M, et al. Probable molecular mechanism of remdesivir for the treatment of COVID-19: need to know more. Arch Med Res. 2020;51(6):585–586. doi: 10.1016/j.arcmed.2020.05.001.
   PubMed Web of Science ®Google Scholar
• Williamson BN, Feldmann F, Schwarz B, et al. Clinical benefit of remdesivir in rhesus macaques infected with SARS-CoV-2. Nature. 2020;585(7824):273–276. doi: 10.1038/s41586-020-2423-5.
   PubMed Web of Science ®Google Scholar
• Beigel JH, Tomashek KM, Dodd LE, et al. Remdesivir for the treatment of Covid-19 - final report. N Engl J Med. 2020;383(19):1813–1826. doi: 10.1056/NEJMoa2007764.
   PubMed Web of Science ®Google Scholar
• Pan H, Peto R, , et al. Remdesivir and three other drugs for hospitalised patients with COVID-19: final results of the WHO Solidarity randomised trial and updated meta-analyses. Lancet. 2022;399(10339):1941–1953. doi: 10.1016/S0140-6736(22)00519-0.
   PubMed Web of Science ®Google Scholar
• Gottlieb RL, Vaca CE, Paredes R, et al. Early remdesivir to prevent progression to severe Covid-19 in outpatients. New Engl J Med. 2022;386(4):305–315.
   PubMed Web of Science ®Google Scholar
• Okoli GN, Rabbani R, Copstein L, et al. Remdesivir for coronavirus disease 2019 (COVID-19): a systematic review with meta-analysis and trial sequential analysis of randomized controlled trials. Infect Dis-Nor. 2021;53(9):691–699.
   PubMed Web of Science ®Google Scholar
• Rezagholizadeh A, Khiali S, Sarbakhsh P, et al. Remdesivir for treatment of COVID-19; an updated systematic review and meta-analysis. Eur J Pharmacol. 2021;897:173926. doi: 10.1016/j.ejphar.2021.173926.
   PubMed Web of Science ®Google Scholar
• Lai CC, Chen CH, Wang CY, et al. Clinical efficacy and safety of remdesivir in patients with COVID-19: a systematic review and network meta-analysis of randomized controlled trials. J Antimicrob Chemother. 2021;76(8):1962–1968. doi: 10.1093/jac/dkab093.
   PubMed Web of Science ®Google Scholar
• Angamo MT, Mohammed MA, Peterson GM. Efficacy and safety of remdesivir in hospitalised COVID-19 patients: a systematic review and meta-analysis. Infection. 2022;50(1):27–41. doi: 10.1007/s15010-021-01671-0.
   PubMed Web of Science ®Google Scholar
• Al-Abdouh A, Bizanti A, Barbarawi M, et al. Remdesivir for the treatment of COVID-19: a systematic review and meta-analysis of randomized controlled trials. Contemp Clin Trials. 2021;101:106272. doi: 10.1016/j.cct.2021.106272.
   PubMed Web of Science ®Google Scholar
• Higgins J, Lasserson T, Chandler J, et al. Methodological Expectations of Cochrane Intervention Reviews (MECIR). London Cochrane; 2016.
   Google Scholar
• Page MJ, McKenzie JE, Bossuyt PM, et al. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ. 2021;372:n71. doi: 10.1136/bmj.n71.
   PubMed Web of Science ®Google Scholar
• Okoli GN, Rabbani R, Al-Juboori A, et al. Antiviral drugs for coronavirus disease 2019 (COVID-19): a systematic review with network meta-analysis. Expert Rev anti-Infe. 2022;20(2):267–278.
   PubMed Web of Science ®Google Scholar
• McGowan J, Sampson M, Salzwedel DM, et al. PRESS peer review of electronic search strategies: 2015 guideline statement. J Clin Epidemiol. 2016;75:40–46. doi: 10.1016/j.jclinepi.2016.01.021.
   PubMed Web of Science ®Google Scholar
• Chen Q, Allot A, Lu Z. Keep up with the latest coronavirus research. Nature. 2020;579(7798):193–193. doi: 10.1038/d41586-020-00694-1.
   PubMed Web of Science ®Google Scholar
• The Cochrane Collaboration. Cochrane COVID-19 Study Register. The Cochrane Collaboration; 2020. https://bit.ly/2TbZssW. Accessed October 7.
   Google Scholar
• World Health Organization. COVID-19: global literature on coronavirus disease. The World Health Organization; 2020. https://bit.ly/34knI2B. Accessed October 7.
   Google Scholar
• Epistemonikos Foundation. L·OVE Platform: COVID-19 Evidence. Epistemonikos Foundation. https://bit.ly/3wk1WZ0. Published 2021. Accessed October 7, 2021.
   Google Scholar
• WHO Working Group on the Clinical Characterisation and Management of COVID-19 infection. A minimal common outcome measure set for COVID-19 clinical research. Lancet Infect Dis. 2020;20(8):e192–e197.
   PubMed Web of Science ®Google Scholar
• Sterne JAC, Savović J, Page MJ, et al. RoB 2: a revised tool for assessing risk of bias in randomised trials. BMJ. 2019;366:l4898. doi: 10.1136/bmj.l4898.
   PubMed Web of Science ®Google Scholar
• Luo D, Wan X, Liu J, et al. Optimally estimating the sample mean from the sample size, median, mid-range, and/or mid-quartile range. Stat Methods Med Res. 2018;27(6):1785–1805. doi: 10.1177/0962280216669183.
   PubMed Web of Science ®Google Scholar
• Wan X, Wang W, Liu J, et al. Estimating the sample mean and standard deviation from the sample size, median, range and/or interquartile range. BMC Med Res Methodol. 2014;14(1):135. doi: 10.1186/1471-2288-14-135.
   PubMed Web of Science ®Google Scholar
• Higgins JP, Thompson SG. Quantifying heterogeneity in a meta-analysis. Stat Med. 2002;21(11):1539–1558.
   PubMed Web of Science ®Google Scholar
• Sterne JA, Egger M, Smith GD. Systematic reviews in health care: investigating and dealing with publication and other biases in meta-analysis. BMJ. 2001;323(7304):101–105. doi: 10.1136/bmj.323.7304.101.
   PubMed Web of Science ®Google Scholar
• Atkins D, Best D, Briss PA, et al. Grading quality of evidence and strength of recommendations. BMJ. 2004;328(7454):1490. doi: 10.1136/bmj.328.7454.1490.
   PubMed Web of Science ®Google Scholar
• Wetterslev J, Thorlund K, Brok J, et al. Trial sequential analysis may establish when firm evidence is reached in cumulative meta-analysis. J Clin Epidemiol. 2008;61(1):64–75. doi: 10.1016/j.jclinepi.2007.03.013.
   PubMed Web of Science ®Google Scholar
• Ader F, Bouscambert-Duchamp M, Hites M, et al. Remdesivir plus standard of care versus standard of care alone for the treatment of patients admitted to hospital with COVID-19 (DisCoVeRy): a phase 3, randomised, controlled, open-label trial. Lancet Infect Dis. 2022;22(2):209–221. doi: 10.1016/S1473-3099(21)00485-0.
   PubMed Web of Science ®Google Scholar
• Ali K, Azher T, Baqi M, et al. Remdesivir for the treatment of patients in hospital with COVID-19 in Canada: a randomized controlled trial. CMAJ. 2022;194(7):E242–E251. doi: 10.1503/cmaj.211698.
   PubMed Web of Science ®Google Scholar
• Barratt-Due A, Olsen IC, Nezvalova-Henriksen K, et al. Evaluation of the Effects of Remdesivir and Hydroxychloroquine on Viral Clearance in COVID-19: a Randomized Trial. Ann Intern Med. 2021;174(9):1261–1269. doi: 10.7326/M21-0653.
   PubMed Web of Science ®Google Scholar
• Goldman JD, Lye DCB, Hui DS, et al. Remdesivir for 5 or 10 Days in Patients with Severe Covid-19. N Engl J Med. 2020;383(19):1827–1837. doi: 10.1056/NEJMoa2015301.
   PubMed Web of Science ®Google Scholar
• Mahajan L, Singh A P, Gifty. Clinical outcomes of using remdesivir in patients with moderate to severe COVID-19: a prospective randomised study. Indian J Anaesth 2021;65(Suppl 1):S41–S46. doi: 10.4103/ija.IJA_149_21.
   PubMedGoogle Scholar
• Spinner CD, Gottlieb RL, Criner GJ, et al. Effect of remdesivir vs standard care on clinical status at 11 days in patients with moderate COVID-19 a randomized clinical trial. Jama-J Am Med Assoc. 2020;324(11):1048–1057. doi: 10.1001/jama.2020.16349.
   PubMed Web of Science ®Google Scholar
• Wang Y, Zhang D, Du G, et al. Remdesivir in adults with severe COVID-19: a randomised, double-blind, placebo-controlled, multicentre trial. Lancet. 2020;395(10236):1569–1578. doi: 10.1016/S0140-6736(20)31022-9.
   PubMed Web of Science ®Google Scholar
• Abd-Elsalam S, Ahmed OA, Mansour NO, et al. Remdesivir efficacy in COVID-19 treatment: a randomized controlled trial. Am J Trop Med Hyg. 2021;107(3):1. doi: 10.4269/ajtmh.1073ret.
   Google Scholar
• Lucijanić M, Bušić N, Bistrović P, et al. Real-life experience with remdesivir for treatment of hospitalized coronavirus disease 2019 patients: matched case-control study from a large tertiary hospital registry. Croat Med J. 2022;63(6):536–543. doi: 10.3325/cmj.2022.63.536.
   PubMed Web of Science ®Google Scholar
• Veronese N, Di Gennaro F, Frallonardo L, et al. Real life experience on the use of Remdesivir in patients admitted to COVID-19 in two referral Italian hospital: a propensity score matched analysis. Sci Rep. 2024;14(1):9303. doi: 10.1038/s41598-024-59957-w.
   PubMedGoogle Scholar
• Gandham R, Eerike M, Raj GM, et al. Adverse events following remdesivir administration in moderately ill COVID-19 patients - A retrospective analysis. J Family Med Prim Care. 2022;11(7):3693–3698. doi: 10.4103/jfmpc.jfmpc_2468_21.
   PubMedGoogle Scholar
• Nabati M, Parsaee H. Potential cardiotoxic effects of remdesivir on cardiovascular System: a literature review. Cardiovasc Toxicol. 2022;22(3):268–272. doi: 10.1007/s12012-021-09703-9.
   PubMed Web of Science ®Google Scholar
• Lucijanic M, Cikara T, Bistrovic P, et al. Remdesivir use in COVID-19 patients might predispose bacteremia, matched case-control analysis. J Infect. 2022;85(2):174–211. doi: 10.1016/j.jinf.2022.04.045.
   PubMed Web of Science ®Google Scholar
• Piscoya A, Ng-Sueng LF, Parra Del Riego A, et al. Efficacy and harms of remdesivir for the treatment of COVID-19: a systematic review and meta-analysis. PLOS One. 2020;15(12):e0243705. doi: 10.1371/journal.pone.0243705.
   PubMed Web of Science ®Google Scholar
• Mazzitelli M, Trunfio M, Sasset L, et al. Risk of hospitalization and sequelae in patients with COVID-19 treated with 3-day early remdesivir vs. controls in the vaccine and Omicron era: A real-life cohort study. J Med Virol. 2023;95(3):e28660.
   PubMed Web of Science ®Google Scholar